Your activity: 58 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Evaluation for other causes of anemia in patients being considered for an erythropoiesis-stimulating agent

Evaluation for other causes of anemia in patients being considered for an erythropoiesis-stimulating agent
  • Thorough drug exposure history
  • Review of a peripheral blood smear and, in some cases, bone marrow examination
  • Analysis for iron, total iron binding capacity, transferrin saturation, ferritin, folate, vitamin B12, or hemoglobinopathy screening (where indicated)
  • Assessment of reticulocyte count, occult blood loss, and renal insufficiency
  • Baseline erythropoietin level
  • Testing of serum thyroid-stimulating hormone level (where indicated)
  • Investigations may also include direct antiglobulin testing (eg, Coombs test) for patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or a history of autoimmune disease
Adapted from: Bohlius J, Bohlke K, Castelli R, et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol 2019. Reprinted with permission. Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
Graphic 60121 Version 5.0